Building the Case for Optimal Prophylaxis for Growth-Friendly Surgery for Non-idiopathic Scoliosis: Use of Vancomycin and Aminoglycosides

Anas Minkara, Hiroko Matsumoto, Michael Glotzbecker, John Flynn, John Smith, Amer Samdani, Lisa Saiman, Michael Vitale, CSSG
Disclosure: I DO have a financial relationship with a commercial interest.

- **Royalties**: Biomet, ECOP
- **Consultant**: Stryker, Biomet, Nuvasive; Wellinks
- **Research Support**: CWSDRF, SRS, POSNA; OREF
- **Travel Support**: CWSDSG, FoxPSDSG
- **BOD**: CSSG, IPOS, SSS
BPG for Optimal Prophylaxis of SSI in “High Risk” Patients

- JPO 2013
- Consensus re need for gram negative prophylaxis
- Did not specifically focus on EOS

1. Patients should have a chlorhexidine skin wash at home the night before surgery.*
2. Patients should have preoperative urine cultures obtained and treated if positive.*
3. Patients should receive a preoperative Patient Education Sheet.*
4. Patients should have a preoperative nutritional assessment.*
5. If removing hair, clipping is preferred to shaving.†
6. Patients should receive perioperative intravenous cefazolin.*
7. Patients should receive perioperative intravenous prophylaxis for gram-negative bacilli.*
8. Adherence to perioperative antimicrobial regimens should be monitored (ie, agent, timing, dosing, readosing, cessation).*
9. Operating room access should be limited during scoliosis surgery whenever practical.*
10. Ultraviolet lights need not be used in the operating room.*
11. Patients should have intraoperative wound irrigation.*
12. Vancomycin powder should be used in the bone graft and/or the surgical site.†
13. Impervious dressings are preferred postoperatively.†
14. Postoperative dressing changes should be minimized before discharge to the extent possible.†
Consensus for SSI prevention guidelines in EOS patients

- Glotzbecker et al. (SRS, 2015) developed guidelines with the EOS population.
- **Use of Vanc Powder but no consensus on GNR prophylaxis**

1. All patients should receive perioperative intravenous cefazolin prior to an insertion or lengthening procedure.
2. Vancomycin powder should be used in the bone graft/and or surgical site for insertion procedures.
3. Patients should receive a preoperative Patient Education Sheet.
4. Patient should have a pulmonary workup evaluation if there is a history of respiratory problems.
5. Prep should be wide enough to place a chest tube within the surgical field
6. Adherence to perioperative antimicrobial regimens should be monitored
7. Soft tissue handling and incision planning in important in preventing postoperative infections for insertion and lengthening procedures
8. Patients should have intraoperative wound irrigation
9. If removing hair prior to an insertion procedure, clipping is preferred to shaving
10. When compared to other skin preparations, chlorhexidine is preferred
11. Operating room access should be limited during scoliosis surgery when practical
12. All previous scars/incisions should be prepped in the surgical field
Gram Negative Rod (GNR) are common cause of SSI in EOS

- Garg et al found in all patients undergoing Vertical Expandable Prosthetic Titanium Rib (VEPTR) surgery from 2007 – 2013, GNR comprised 20% of all deep SSI.

- Sponseller et al. found 52% of deep SSI in neuromuscular patients undergoing surgery from 1986 – 1996 were Gram Negative Rods (GNR)
Moving Target?

• Changes in multiple strategies simultaneously (CHG, in wound vancomycin, betadine etc)

• Shift from multiple procedures to MAGEC

• Has microbiology changed and what should be the ideal prophylaxis in 2017?
Utilize CSSG to:

**Identify microbiology and susceptibilities of SSIs following growth-friendly surgery**

**Explore prophylaxis regimens used throughout CSSSG and examine changes over time**
Methods

Design and Setting

• Retrospective cohort study
• Multi Center National Registry – 11 participating sites
• Children’s Spine Study Group Registry (CSSG)
• Growth friendly instrumentation (excludes magnetically controlled growing rods, MAGEC) performed between 09/2001 – 01/2016
Methods

**Inclusion Criteria**
1. Non-Idiopathic Scoliosis
2. <18 years of age
3. Growth friendly instrumentation

**Endpoints**
1. Pathogens from SSI cultures (CDC: SSI occurring ≤ 90 days)
2. Susceptibility profiles of pathogens
3. Perioperative prophylaxis regimen
593 EOS patients; 75 SSI

- 75 (12.6%) patients had 99 total SSIs reported

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>N = 593</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age at implant (years)</td>
<td>5.9 (0.5 – 17.9)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>273 (46%)</td>
</tr>
<tr>
<td>Female</td>
<td>320 (54%)</td>
</tr>
<tr>
<td>EOS Etiology</td>
<td></td>
</tr>
<tr>
<td>Congenital</td>
<td>267 (45%)</td>
</tr>
<tr>
<td>Neuromuscular</td>
<td>231 (39%)</td>
</tr>
<tr>
<td>Syndromic</td>
<td>95 (16%)</td>
</tr>
</tbody>
</table>
**Type of Pathogen** | **Number of cultures (%)**
--- | ---
**Gram-positive Cocci** | 82/91 (90.1%)  
Methicillin-susceptible Staphylococcus aureus | 44/91 (48.3%)  
**Methicillin-resistant Staphylococcus aureus** | 21/91 (23.1%)  
Coagulase negative staphylococci* | 5/91 (5.5%)  
Unspecified S. aureus | 6/91 (6.6%)  
Group A streptococcus* | 4/91 (4.4%)  
Enterococcus faecalis | 2/91 (2.2%)
Gram negative rods comprise 16.5% of all SSI cultures

<table>
<thead>
<tr>
<th>Type of Pathogen</th>
<th>Number of cultures(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-negative Rods</strong></td>
<td>15/91 (16.5%)</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>5/91 (5.5%)</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>4/91 (4.4%)</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa*</td>
<td>3/91 (3.3%)</td>
</tr>
<tr>
<td>Klebsiella pneumonia or K. oxytoca*</td>
<td>2/91 (2.2%)</td>
</tr>
<tr>
<td>Acinetobacter baumannii</td>
<td>1/91 (1.1%)</td>
</tr>
</tbody>
</table>
GNR have good but not universal susceptibility to aminoglycosides.
GPC have limited susceptibility to Cefazolin but highly susceptible to Vancomycin

- Cefazolin: 59.3%
- Vancomycin: 97.4%
GNR susceptibility to aminoglycosides increased over time- no evidence of resistance!

![Graph showing percentage susceptible to Cefazolin and Aminoglycoside over time from 2001-2016]

- Cefazolin
- Aminoglycoside
No change in GPC susceptibility to cefazolin and vancomycin over time
Current Prophylaxis Practice and Guidelines

- 100% of 11 institutions used cefazolin and intravenous or topical vancomycin
- 78% used aminoglycosides for Gram negative coverage
Conclusion

• 16.5% GNR in deep SSI cultures lower than 52% (Sponseller et al.) and 20% (Garg et al.)

• Aminoglycosides prophylaxis should be considered for GNR

• Vancomycin prophylaxis (IV or local) should continue to be used for GPC
SAVE THE DATE

3rd Annual

Safety in Spine Surgery Summit

Transforming Patient Care and Optimizing Outcomes

Chair: Michael G. Vitale, MD, MPH
Co-Chairs: John M. Flynn, MD, Lawrence G. Lenke, MD, Paul C. McCormick, MD, Rajiv K. Sethi, MD

An ESSENTIAL program for:
- Spine surgeons
- Surgical spine team members

Friday, April 20, 2018
New York City